BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment
News
Myriad Genetics‘ BRACAnalysis CDx has been approved by the U.S. Food and Drug Administration as a companion diagnostic test to identify women with ovarian cancer eligible for first-line maintenance treatment with Lynparza (olaparib). ... Read more